Genmab — September 2023
-
For mig ser det ud som om, at markedet er ved at indprise en tabt voldgift i Genmab kursen. Jeg kan ikke se ret mange andre årsager. Håber, vi snart får en afgørelse. Må indrømme, at jeg har lidt svært ved at se, en US voldgift gå Genmab’s vej. Men lad os se, håbet lever.
-
Måske en fat finger
-
Plejer at komme efter midnat fredag/lørdag
-
Jeg har observeret, at der, generelt ofte sker mærkværdige ting hhv. kl. 13:30 og kl. 14.30
-
Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT
(amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer https://www.prnewswire.com/news-releases/landmark-phase-3-mariposa-study-meets-primary-endpoint-resulting-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-for-rybreva
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind